J Gynecol Oncol.  2013 Jul;24(3):209-211. 10.3802/jgo.2013.24.3.209.

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer

• Pujade-Lauraine E

• KMID: 2288525
• DOI: http://doi.org/10.3802/jgo.2013.24.3.209

Abstract

No abstract available.

MeSH Terms

Antibodies, Monoclonal, Humanized
Bevacizumab
Cyclophosphamide
Ovarian Neoplasms
Antibodies, Monoclonal, Humanized
Cyclophosphamide

Reference

1. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365:2473–2483.

2. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365:2484–2496.

3. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012; 30:2039–2045.

4. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [abstract]. J Clin Oncol. 2012; 30:18 Suppl. LBA5002.

5. Barber EL, Zsiros E, Lurain JR, Rademaker A, Schink JC, Neubauer NL. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for recurrent platinum resistant ovarian cancer. J Gynecol Oncol. 2013; 24:258–264.

6. Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res. 2013; 73:3347–3355.

7. Handolias D, Quinn M, Foo S, Mileshkin L, Grant P, Dutu G, et al. Oral cyclophosphamide in recurrent ovarian cancer. Asia Pac J Clin Oncol. 2013; 05. 29. [Epub]. http://dx.doi.org/10.1111/ajco.12074.

8. Vives M, Ginesta MM, Gracova K, Graupera M, Casanovas O, Capella G, et al. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int J Cancer. 2013; 05. 07. [Epub]. http://dx.doi.org/10.1002/ijc.28259.

9. Kandalaft LE, Chiang CL, Tanyi J, Motz G, Balint K, Mick R, et al. A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med. 2013; 11:149.

10. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008; 26:76–82.